Table 2.
Participants’ characteristics
| Definition 1 (n = 318) |
Definition 2 (n = 313*) |
Definition 3 (n = 318) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aβ- | Low burden | Aβ+ | Aβ- | Low burden | Aβ+ | Aβ- | Low burden | Aβ+ | ||||
| CSF- CL < 30 (n = 205, 64.5%) |
CSF+ CL < 30 (n = 88, 27.7%) |
CSF+ CL > 30 (n = 25, 7.86%) |
P value | CSF- VR- (n = 202, 64.5%) |
CSF+ VR- (n = 72, 23.0%) |
CSF+ VR+ (n = 39, 12.5%) |
P value | CL < 20 (n = 281, 88.4%) |
20 - 40 CL (n = 18, 5.66%) |
CL > 40 (n = 19, 6.0%) |
P value | |
| Age, years | 60.5 (4.32) | 61.2 (5.14) | 65.7 (2.64)1,2 | <0.0001 | 60.5 (4.34) | 60.8 (5.23) | 64.9 (3.41)1,2 | <0.0001 | 60.6 (4.61) | 64.0 (3.53)3 | 65.5 (2.89)1 | <0.0001 |
| Female, n (%) | 133 (64.9) | 48 (54.5) | 18 (72.0) | 0.12 | 131 (64.9) | 40 (55.6) | 24 (61.5) | 0.37 | 175 (62.3) | 11 (61.1) | 13 (68.4) | 0.86 |
| Education, years | 13.4 (3.44) | 13.7 (3.44) | 12.2 (3.95) | 0.19 | 13.6 (3.40) | 13.5 (3.30) | 12.5 (3.89) | 0.20 | 13.5 (3.42) | 13.3 (3.85) | 12.5 (3.99) | 0.53 |
| MMSE | 29.1 (0.98) | 29.4 (0.91) | 28.9 (1.09) | 0.10 | 29.1 (0.95) | 29.3 (0.90) | 29.0 (1.09) | 0.25 | 29.2 (0.95) | 29.2 (1.04) | 29.1 (1.03) | 0.90 |
| APOE-ε4 carriers, n (%) | 85 (41.5) | 70 (79.5)1 | 17 (68.0) | <0.0001 | 82 (40.6) | 57 (79.2)1 | 28 (71.8)3 | <0.0001 | 145 (51.6) | 13 (72.2) | 14 (73.7) | 0.049 |
| Centiloid (CL) | −4.58 (6.51) | 7.06 (10.2)1 | 50.9 (12.6)1,2 | <0.0001 | −4.66 (6.51) | 5.52 (9.40)1 | 36.3 (21.7)1,2 | <0.0001 | −2.17 (7.99) | 28.2 (6.10)1 | 55.6 (10.6)1,2 | <0.0001 |
| CSF Aβ42/40 | 0.087 (0.009) | 0.055 (0.010)1 | 0.040 (0.008)1,2 | <0.0001 | 0.086 (0.009) | 0.056 (0.011)1 | 0.045 (0.011)1,2 | <0.0001 | 0.078 (0.016) | 0.045 (0.010)1 | 0.041 (0.008)1 | <0.0001 |
Data are expressed as mean (M) and standard deviation (SD) or number of participants (n) and percentage (%), as appropriate. One-way ANOVA followed by Tukey corrected post hoc pairwise comparisons was used to compared age, education, and MMSE performance and Pearson’s chi-squared test to compare sex and APOE-ε4 status between groups within each definition. CSF Aβ42/40 and CL were compared with an ANCOVA adjusted by age and sex followed by Tukey corrected post hoc pairwise comparison. The P values indicated in the last column refer to the group main effect. Significant P values are marked in bold. “Low burden” refers to “Low burden of Ab pathology”. Abbreviations: Aβ amyloid-β, CL Centiloid, CSF cerebrospinal fluid, MMSE mini-mental state examination, VR visual read
*In definition 2, we included 313 participants because 2 participants did not have Aβ PET visual read assessment available and 3 additional participants had a discrepant CSF and visual read assessment (negative CSF Aβ42/40 ratio but positive visual read). Participants with this biomarker profile do not fall in any of the definition 2 categories
1P < 0.0001 vs Aβ- group
2P < 0.0001 vs low burden group
3P < 0.01 vs Aβ- group